- Daniel Caesar dons cape for whiteness—and gets canceled Wednesday 4:29 PM
- Triton is a new malware ‘deliberately’ designed to put lives at risk Wednesday 3:23 PM
- ‘Into the Dark: I’m Just F*cking with You’ is one of the series’ best Wednesday 1:54 PM
- Trump’s latest prop, a map of ISIS, gets memed Wednesday 12:54 PM
- HBO sends fans on a global scavenger hunt for 6 Iron Thrones Wednesday 11:51 AM
- The Awkward Family Photos game is Cards Against Humanity for meme lovers Wednesday 11:50 AM
- London firefighters’ organization accuses ‘Peppa Pig’ of sexism Wednesday 11:41 AM
- YouTuber accused of abusing her children to make kid-friendly content Wednesday 11:20 AM
- Ari Fleischer’s Iraq War tweet isn’t going over well Wednesday 10:54 AM
- Cop arrested for recording man’s genitals, forcing mentally ill man to twerk Wednesday 10:37 AM
- MoviePass rebrands its unlimited plan, again Wednesday 10:37 AM
- Former Alaska senator launches meme-filled 2020 primary campaign Wednesday 10:17 AM
- The Shane Dawson cat controversy has resulted in these sex memes Wednesday 10:06 AM
- Sarah Sanders mocks CNN reporter with ‘dear diary’ tweet Wednesday 9:03 AM
- Know what you’re signing up for thanks to these dating site reviews Wednesday 8:58 AM
The FDA slams Kim Kardashian for promoting prescription drug on Instagram
Maybe don’t get your medical advice from Kim Kardashian’s Instagram account.
Kim Kardashian is famously famous for being famous. Whatever she does attracts attention, especially on social media. And wherever there’s a shiny thing for people to look at, there will be brands clamoring to put advertisements all over that space.
It’s the circle of thirst, and it moves us all.
One such advertisement, posted to Kardashian’s Instagram account last month, has attracted the ire of the Food and Drug Administration. The post, which Kardashian also linked to on her Twitter account, extolled the benefits of a medication designed to ease the symptoms of morning sickness.
In a warning letter dated Aug. 7, the FDA charges that Kardashian’s promotion of the drug, Diclegis, “[is] false or misleading in that it presents efficacy claims for Diclegis, but fails to communicate any risk information associated with its use and it omits material facts.”
“These violations are concerning from a public health perspective because they suggest that Diclegis is safer than has been demonstrated,” continues the letter, which ordered Duchesnay, the drug’s manufacturer, to have the post taken down.
The FDA’s problem with Kardashian’s post is that, while the drug has been approved for public use, the Keeping Up with the Kardashians star didn’t include any mention of its possibly very serious side effects—a necessary part of any drug advertisement in the United States.
While the post concluded with Kardashian urging her followers to consult their doctors before trying Diclegis and directed them to a pair of websites with information about the drug, those disclosures weren’t sufficient for the FDA. “This does not mitigate the misleading omission of risk information,” the letter insists.
Between her Twitter and Instagram accounts, Kardashian has nearly 77 million followers. As such, her social media feeds are valuable real estate for advertisers looking to reach a large quantity of people who have already voluntarily signed up to read what Kardashian has to say.
Many famous people with large social media followings have taken to acting as online pitchmen and women for brands as an easy way to earn revenue. New York reports rapper Snoop Dogg earns $8,000 per tweet and singer/reality TV star Paula Abdul gets about $5,000 per 140-character missive. In the middle of his public meltdown, Charlie Sheen was reportedly making $50,000 every time he plugged a brand on Twitter.
H/T Washington Post | Photo by The Heart Truth/Wikimedia Commons (public domain)
Aaron Sankin is a former Senior Staff Writer at the Daily Dot who covered the intersection of politics, technology, online privacy, Twitter bots, and the role of dank memes in popular culture. He lives in Seattle, Washington. He joined the Center for Investigative Reporting in 2016.